U.S. Supreme Court Denies Cert to Mirena MDL Plaintiffs
The U.S. Supreme Court has denied a petition for writ of certiorari filed by plaintiffs in the Mirena® multidistrict litigation, effectively ending litigation in federal courts that involved more than 1,300 plaintiffs and lasted more than five years.
Shook Team Obtains Third Win This Year for Pharmacia
A Shook team has obtained their third win in a year for Pharmacia & Upjohn Co. LLC (Pharmacia), the maker of the corticosteroid drug Depo-Medrol® (methylprednisone acetate).
Shook Obtains Back-to-Back Wins for Medtronic In Product Liability Cases
Eleventh Circuit Affirms Summary Judgment for Marketers of Enbrel
The Eleventh Circuit has affirmed a lower court’s grant of summary judgment in favor of the makers and marketers of the biologic drug Enbrel, finding that the plaintiffs' injury claims were barred by the learned intermediary doctrine and that the direct “patient labeling requirement” in FDA medication guidelines did not preempt application of the doctrine.
Second Circuit Affirms Dismissal of Mirena MDL
The U.S. Court of Appeals for the Second Circuit has affirmed the dismissal of litigation in which plaintiffs sought recovery for injuries they alleged were caused by Bayer’s intrauterine contraceptive system, Mirena®. Nearly 1,300 cases were certified as part of an MDL in 2013; the U.S. District Court for the Southern District of New York dismissed the cases in July 2016.